Development of a new TLR4 agonist for the treatment of Allergic Rhinitis

NIH RePORTER · NIH · N44 · $1,836,453 · view on reporter.nih.gov ↗

Abstract

The goal of this project is to develop an intranasal TLR4 agonist to treat allergic rhinitis. Such treatment has the potential to provide short-term symptom control as well as long-term disease remission via allergen dependent T and B cell memory responses.

Key facts

NIH application ID: 10488952
Project number: 75N93021C00044-0-9999-1
Recipient: INIMMUNE CORPORATION
Principal Investigator: JUHIENAH KHALAF
Activity code: N44
Funding institute: NIH
Fiscal year: 2021
Award amount: $1,836,453
Award type: —
Project period: 2021-09-01 → 2023-08-31